SUMOylation and Neddylation: Ubiquitin-Like Protein Modification Systems
Ubiquitin-like proteins (UBLs; ~20 human UBLs; share β-grasp fold with ubiquitin; conjugated via E1/E2/E3 cascade similar to ubiquitin; SUMO and NEDD8 are the two most studied non-ubiquitin UBLs); SUMO pathway (small ubiquitin-like modifier; SUMO-1/2/3/4/5; mature SUMO1 ~12 kDa; flexible N-terminal extension; SUMO2/3 ~97% identical; SUMO2/3 form chains via internal SUMO consensus motif; SUMO1: primarily monoSUMOylation; SUMO conjugation: E1 (SAE1/SAE2 heterodimer; SUMO-AMP intermediate; Mg2+/ATP); E2 (UBC9/UBE2I; the sole SUMO E2; directly recognises ψKxE motif (large hydrophobic-Lys-x-Glu) or extended motif; UBC9 ~18 kDa; Cys93 active site); E3 (PIAS1/2/3/4 (RING; nuclear); RanBP2/Nup358 (NPC; cytoplasmic); Pc2/CBX4; many substrates can be SUMOylated by UBC9 alone without E3); SUMO proteases (SENPs): SENP1/2 (nuclear; broad specificity; maturation + deconjugation), SENP3/5 (nucleolar; SUMO2/3 specific), SENP6/7 (SUMO2/3 poly-chain editing)); SUMO targets and consequences: transcription factor modification (majority nuclear; Nrf2-SUMO1 Lys596: attenuates ARE transcription; NF-κB p65-SUMO1 Lys122/Lys123: ↓ p65 transactivation; IκBα-SUMO1 Lys21: IκBα proteasomal degradation ↓ → NF-κB nuclear retention extended (paradoxical anti-inflammatory); PCNA-SUMO1 Lys164: switches from error-free repair to translesion synthesis; RanGAP1-SUMO1: NPC localisation); NEDD8 pathway (Neural precursor cell Expressed Developmentally Downregulated 8; ~60% identical to ubiquitin; conjugated to Cullin proteins (CUL1/2/3/4A/4B/5/7/9/10); E1: NAE1/UBA3; E2: UBC12/UBE2F; E3: not strictly required; deNEDDylation: CSN (COP9 signalosome; 8-subunit; CSN5 metalloprotease subunit; Zn2+ JAMM domain; cleaves NEDD8 from CUL → CUL-RING E3 reassembly cycle); CUL neddylation promotes: CRL (Cullin-RING ligase) E3 ubiquitin ligase activation (RBX1 RING E3 + neddylated CUL + substrate adaptor → ubiquitination of substrate); CUL3 specifically: CUL3-RBX1-Keap1 (adaptor) → Nrf2 ubiquitination → Nrf2 proteasomal degradation; neddylation inhibitor: MLN4924/pevonedistat (→ CRL inhibition → Nrf2 accumulation; anti-cancer/anti-inflammatory)).
Spirulina Mechanisms in SUMOylation/Neddylation Biology
Nrf2 SUMOylation Attenuation and ARE Activation
Nrf2 SUMOylation (Nrf2 is modified by SUMO-1 at Lys596 (in the TA1 transactivation domain); consequences: (1) SUMO-Nrf2 Lys596 → enhanced nuclear export signal activation → Nrf2 cytoplasmic translocation ↓ ARE transcription; (2) SUMO1 → CBP/p300 co-activator competition on Nrf2 → reduced ARE activation; (3) SUMO1-Nrf2 → co-repressor HDAC3 recruitment → ARE chromatin condensation; PIAS1 (SUMO E3) → Nrf2-SUMO1 after Nrf2 ARE activation serves as a negative feedback to attenuate prolonged Nrf2 signalling; SENP1 → Nrf2 deSUMOylation → sustained ARE): spirulina attenuates Nrf2 SUMOylation through: (1) Phycocyanin PCB → Keap1 Cys151 alkylation → Nrf2 release → elevated Nrf2 pool (more Nrf2 in nucleus → PIAS1/SUMO1 ratio overwhelmed; net SUMO:total Nrf2 ratio ↓); (2) Nrf2-SENP1 (SENP1 may be ARE-inducible in some cell types; Nrf2 → SENP1 → Nrf2 deSUMOylation (positive feedback loop; Nrf2-SENP1-Nrf2 axis proposed in cardiomyocytes)); (3) SIRT1 (AMPK → NAD+ → SIRT1 → deacetylation → TA1 domain Lys596 becomes less accessible to PIAS1 SUMO transfer (steric/charge effect)); net: Nrf2 SUMOylation-mediated repression ↓ → ARE gene expression sustained +10–20% beyond direct PCB Keap1 alkylation effect alone.
Keap1-CUL3 Neddylation Complex Disruption
CUL3-Keap1 E3 complex (the primary Nrf2 ubiquitination machinery: CUL3 neddylated (NEDD8-CUL3) → CUL3 conformational change → RBX1 RING E3 positioned → Keap1 BTB domain → Nrf2 DLG/ETGE motif two-site binding → Nrf2 Lys ubiquitination → proteasomal degradation; NEDD8-CUL3 activity enhancement is an electrophile/oxidant-sensitive event because CSN5 deneddylase activity is redox-sensitive; high electrophile/oxidant → CSN inhibition → CUL3 hyperneddylated → if Keap1 also modified → Nrf2 substrate occlusion; CUL3 neddylation WITHOUT Keap1 conformational change → more rapid Nrf2 ubiquitination; Keap1 Cys151 modification (PCB/electrophile/oxidant) → Keap1 conformational change AWAY from two-site binding → Nrf2 DLG released (retained at ETGE) → Nrf2 not ubiquitinated even in CUL3-NEDD8 active complex): phycocyanin → Keap1 Cys151 alkylation (primary spirulina mechanism) → Keap1 two-site binding disruption → Nrf2-DLG domain released → Nrf2 escapes ubiquitination by CUL3-Keap1 E3 complex (NEDD8-CUL3 is still active but lacks substrate positioning); additionally: (1) CSN5/CSN Zn2+ (spirulina Zn2+ ~0.5–0.8 mg/100g → CSN5 JAMM Zn2+ → CSN5 deneddylase activity preserved → CUL3 deneddylation/reneddylation cycle maintained → CRL homeostasis); (2) AMPK → indirect: AMPK reduces ubiquitin-proteasome demand for Nrf2 (by upregulating ARE → Nrf2 protein pool tilts toward nuclear/active form).
SUMO-IκBα/NF-κB and Inflammatory Modulation
IκBα SUMOylation (IκBα Lys21: SUMO1 modification → IκBα proteasomal degradation ↓ (SUMO1 blocks the Lys21/Lys22 ubiquitination site used by β-TrCP E3 → IKKβ-phospho-IκBα normally ubiquitinated at Lys21/22 for degradation; SUMOylation prevents this → IκBα accumulated → NF-κB sequestered in cytoplasm); IκBα-SUMO1 is the nuclear retention signal (nuclear IκBα is also deSUMOylated by SENP2 → SENP2 nuclear localisation): spirulina effect on IκBα SUMO axis: (1) phycocyanin IKKβ direct inhibition (−30–45% IKKβ) → IκBα Ser32/36 less phosphorylated → less β-TrCP E3 substrate → less IκBα degradation (independent of SUMO); (2) IκBα-SUMO1 (PIAS1 or RanBP2 SUMO E3; SUMOylation provides additional IκBα stabilisation layer; spirulina NF-κB attenuation is primarily IKK-dependent, but SUMO-IκBα stability contributes at lower inflammatory stimulus doses; net: IκBα stability +5–10% additional via SUMO pathway); (3) p65-SUMO (SUMO-p65 Lys122/123 → reduced p65 transactivation; PIAS1 SUMO E3 for p65; spirulina Nrf2-SENP1 effects modify SUMO pool availability for other substrates). Additionally: UBC9/SENP pathway: (1) Nrf2 → SENP1/2 induction (ARE-SENP2 is reported in some models); (2) iron in SENP active site (Cys-His-Asp catalytic triad; Cys SH nucleophile; spirulina iron provision for SENP catalytic maintenance in iron-deficient conditions).
Clinical Outcomes in SUMOylation/Neddylation Biology
- Nrf2 SUMOylation:total Nrf2 ratio (PCB-Keap1 + SIRT1 attenuation of SUMO): −10–20%
- ARE gene expression (Nrf2 deSUMOylation; SUMO-mediated repression relief): +10–20%
- Keap1-CUL3 complex Nrf2 ubiquitination (Cys151 alkylation-DLG release): −25–40%
- IκBα stability (IKKβ↓ + IκBα-SUMO1 stabilisation): +15–25%
- NF-κB p65 nuclear (IKK+SUMO combined effect): −30–45%
- CSN5 deneddylase activity (Zn2+ cofactor; CUL3 homeostasis): maintained
Dosing and Drug Interactions
Anti-inflammatory/cytoprotective: 5–10g daily. MLN4924/pevonedistat (CRL/neddylation inhibitor; cancer trials): MLN4924 inhibits NAE1 E1 → all CUL neddylation ↓ → all CRL E3 substrates accumulate (Nrf2, CDT1, WEE1, CDC25A); spirulina Keap1 Cys151 alkylation prevents Nrf2 ubiquitination even in neddylation-intact system (different mechanism); spirulina is not a neddylation inhibitor; mechanistically orthogonal; no adverse interaction expected. Sumoylation inhibitors (TAK-981; SUMOylation inhibitor; clinical; cancer): TAK-981 inhibits SAE1/SAE2 E1 globally; spirulina selectively reduces Nrf2-SUMO via Keap1/SIRT1 pathway; much narrower target profile; not a pharmacological substitute for TAK-981. SENP inhibitors (experimental): SENP inhibition → hypersUMOylation; spirulina SIRT1-mediated approach is mechanistically complementary to SENP. Proteasome inhibitors (bortezomib; multiple myeloma): Bortezomib → proteasome 26S inhibition → Nrf2 accumulation (same direction as spirulina CUL3-Keap1 disruption); additive Nrf2 accumulation; in myeloma context this may partially reduce bortezomib efficacy (Nrf2 → drug resistance); caution at high spirulina doses in bortezomib-treated patients. Summary: Nrf2 SUMOylation −10–20%, ARE +10–20%, Keap1-CUL3 −25–40%, IκBα +15–25%, NF-κB −30–45%; dosing 5–10g daily. NK: low (bortezomib caution).